Mechanism of Cancer Cell Death by Novel Hybrid TPR Peptide Targeting Hsp90
スポンサーリンク
概要
- 論文の詳細を見る
- 2011-03-01
著者
-
Kawakami Koji
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University
-
Ohara Koji
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University
-
HORIBE Tomohisa
Depaartment of Pharamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto Universit
-
KOHNO Masayuki
Depaartment of Pharamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto Universit
-
HARAMOTO Mari
Depaartment of Pharamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto Universit
-
OHARA Koji
Depaartment of Pharamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto Universit
-
KAWAKAMI Koji
Depaartment of Pharamacoepidemiology, Graduate School of Medicine and Public Health, Kyoto Universit
-
HARAMOTO Mari
Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University
-
Haramoto Mari
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University
-
Kohno Masayuki
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University
-
Horibe Tomohisa
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University
-
Kohno Masayuki
Department Of Pharmacoepidemiology Graduate School Of Medicine And Public Health Kyoto University:department Of R & D Promotion Upstream Infinity Inc.
関連論文
- Antedrug Budesonide by Intrapulmonary Treatment Attenuates Bleomycin-Induced Lung Injury in Rats with Minimal Systemic Adverse Effects
- Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development
- Characterization of a novel Neuropilin-1 targeted hybrid peptide disintegrating cancer cell membrane
- Mechanism of Cancer Cell Death by Novel Hybrid TPR Peptide Targeting Hsp90
- Antitumor effect of the EGFR-lytic hybrid peptide in animal model of human cancers with K-ras mutation
- Effective in vitro and in vivo Antitumor Activity of Hybrid IL4-lytic Peptide
- A Novel Hybrid Peptide That Binds Transferrin Receptor and Induces Rapid Permeation of Cancer Cell Membrane
- Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90(MEDICAL BIOTECHNOLOGY)